Abstract
Methotrexate, the mainstay of treatment in Juvenile idiopathic arthritis, might not be effective in a few patients of polyarticular and systemic onset juvenile idiopathic arthritis. Use of biologicals like TNF-α blockers, the next line of preferred drugs is constrained by the high cost. We successfully used leflunomide in four patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Fox RI. Mechanism of action of leflunomide in rheumatoid arthritis, J Rheumatol (Suppl.) 1998;53:20–26.
Silverman E, Mouy R, Spiegel L, Jung LK, Saurenmann RK, Lahdenne P, et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. NEJM. 2005;352:655–666.
Silverman E, Spiegel L, Hawkins D, Petty R, Goldsmith D, Schanberg L, et al. Long term open label preliminary study of safety and efficacy of leflunomide in patients with polyarticular-course in juvenile rheumatoid arthritis. Arthritis Rheum. 2005;52:554–562.
Osiri M, Shea B, Robinson V, Suarez-Almazor M, Strand V, Tugwell P, et al. Leflunomide for the treatment of rheumatoid arthritis: A systematic review and metaanalysis. J Rheumatol. 2003;30:1182–1190.
Foeldvari I, Wierk A. Effectiveness of leflunomide in patients with juvenile idiopathic arthritis in clinical practice. J Rheumatol. 2010;37:1763–1767.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jahan, A., Dewan, V. & Yadav, T.P. Leflunomide in systemic onset juvenile idiopathic arthritis. Indian Pediatr 49, 750–752 (2012). https://doi.org/10.1007/s13312-012-0139-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13312-012-0139-9